2021-01-08,"Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021"
2020-12-30,"Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More"
2020-12-29,"Dont Go Bargain Hunting on Aprea Stock, Says Analyst"
2020-12-29,Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
2020-12-28,10 Biggest Stock Gainers and Losers Today
2020-12-28,Aprea Shares Slump After Cancer-Drug Trial Misses Key Goal
2020-12-28,Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
2020-12-10,Is APRE A Good Stock To Buy Now?
2020-11-30,Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
2020-11-23,3 Stocks with Jaw-Dropping Growth Potential
2020-11-19,Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
2020-11-05,Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
2020-10-30,Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
2020-10-14,"Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com"
2020-10-07,"Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548"
2020-09-29,Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
2020-09-29,"Should You Take Comfort From Insider Transactions At Aprea Therapeutics, Inc. (NASDAQ:APRE)?"
2020-09-18,Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
2020-09-03,Aprea Therapeutics to Present at Upcoming Investor Conferences
2020-08-11,Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
2020-07-16,Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
2020-07-01,How Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry
2020-07-01,2 Biotech Stocks That Could Soar in 2020
2020-07-01,We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
2020-06-29,"Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors"
2020-06-12,"Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE)"
2020-06-12,Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
2020-06-11,Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher
2020-06-10,Is Aprea Therapeutics Stock a Buy?
2020-06-03,Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
2020-05-27,Arcos Dorados (ARCO) in Focus: Stock Moves 10.8% Higher
2020-05-18,Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
2020-05-15,Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
2020-05-11,Why Aprea Therapeutics (APRE) Stock Might be a Great Pick
2020-04-27,"INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims"
2020-04-06,Aprea Therapeutics Launches New Corporate Website - www.aprea.com
2020-04-02,"Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?"
2020-03-26,Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-02-13,"Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial"
2020-01-30,Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
2020-01-09,"Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020"
2020-01-03,We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
2019-12-17,Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
2019-12-12,Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
2019-12-09,Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
2019-12-09,Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
2019-12-07,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling"
2019-11-29,Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
2019-11-14,Aprea Therapeutics Reports Third Quarter 2019 Financial Results
2019-11-11,RBC: 3 Stock Picks Set to Soar 30%+
2019-11-06,Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
2019-10-11,Gates-Backed Vir Biotechnology Flops in Trading Debut
2019-10-11,"Insiders Roundup: Facebook, American Defense Systems"
2019-10-08,Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO
2019-10-07,Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
2019-10-03,"Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further"
2019-10-02,Aprea Therapeutics Announces Pricing of Initial Public Offering
2019-09-30,IPO Outlook For The Week: Banks And Biotechs
2019-09-23,"Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each"
